What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy:T esaglitazar (AZ242), an insulin sensitizer, may increase life span via up-regulation of its target gene BubR1
What is known?
Netoglitazone has been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear.
From Research Findings to Therapeutic Opportunity:
This study suggests, for the first time, that Tesaglitazar, by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).
Thereby, it may: (1) increase insulin sensitivity; (2) increase thermogenesis, lipolysis and oxidative metabolism; (3) inhibit obesity; (4) attenuate cognitive impairment; (5) delay diseases of aging; (6) slow down cardiac aging; (7) promote resistance to bone, immune and motor dysfunction; (8) promote tissue rejuvenation; and (9) prolong median life span. Thus, pharmacological formulations encompassing “Tesaglitazar or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How a pharmaceutical mix encompassing Tesaglitazar increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
Citation: Boominathan, L., Lifespan extension therapy:T esaglitazar (AZ242), an insulin sensitizer, may increase life span via up-regulation of its target gene BubR1, 19/October/2017, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org